Our Coronavirus Pandemic Initiative
Joining the global race to find vaccines and treatments to stem the global coronavirus disease pandemic
At InSphero, we want to support organizations worldwide that are working on vaccines and treatments to stem the global coronavirus disease pandemic. Starting on March 24, 2020, we will offer free safety testing for exploratory COVID-19 medications and coronavirus (SARS-COV-2) vaccine formulations. These COVID-19 tests will be based on our 3D InSight™ Human Liver models and available to any organization (academic, governmental or industrial) that wants to conduct risk assessments on their treatments in development. A big shout out to all the researchers who are working so hard on this – we are here for you! Read the press release.
Gain Unrivaled Biological InSight
Investigate with Confidence
Screen and test efficacy of NASH and Fibrosis drugs with a platform that mimics NAFLD progression in humans.
Discover with Confidence
Conduct type 1 & type 2 diabetes research in a platform that ensures uniform, long-lived islets with robust functionality.
Translate with Confidence
Reflect complex 3D tumor microenvironments with tumor, stromal, and immune components.
3D InSight™ platforms include everything you need to optimize your investment in 3D in vitro cell technology: physiologically relevant microtissue models, specially formulated media, 3D-optimized assay protocols, expert support from experienced application scientists, and the option to outsource testing to our services team.
Why Partner with InSphero?
Add the pioneer in 3D cell-based assay solutions and scaffold-free organ-on-a-chip technology to your drug R&D team and see immediate results.
Work with 3D platforms precisely engineered to mimic human biology and save you years of model development and assay testing time.
Rely on functionally robust, highly standardized microtissue models. The microtissue models are reviewed by QA in compliance with InSphero EN ISO 9001 Quality System standards.
Ensure reproducible data and minimize confounding factors regardless of the scale and complexity of your experiments.
“Addressing complex diseases requires the rare combination of pioneering innovation and biomedical expertise. As our discovery partner, InSphero gives us immediate access to new technologies, such as organ-on-a-chip systems, that provide deep mechanistic insights into complex diseases. They have become part of our research team, committed to helping us find a cure for type 1 diabetes.”
MATTHIAS VON HERRATH, MD
Professor and Director of the Center for Type 1 Diabetes Research
La Jolla Institute of Immunology
Vice President and Senior Medical Officer